CEO: Dr. Werner Zoellner
Wellington contact:
Rolf Dienst
| A new kind of a virtual drug development company |
Tinnitus is a virtual drug development company developing innovative therapeutics against tinnitus aurium. After successfully conducting preclinical and clinical development until completion of phase IIa, the company has partnered its lead drug candidate with a large pharma company.
First investment: June 1998
Tinnitus FE GmbH
Flueggenstr. 17
80639 Munich
Germany
